Bioinformatics, Clinical Development and In-Vivo

Astellas teams up with UK biotech Mogrify on hearing loss project

pharmaphorum

JULY 5, 2022

The two partners will take an in vivo approach to the problem of so-called sensorineural hearing loss (SNHL) looking at ways to replace sound-detecting hair cells in the inner ear (cochlea) that become damaged in this type of deafness. An estimated 1.57 Astellas is already working on other approaches to treating hearing loss.

In-Vivo

In-Vivo Bioinformatics Genetics Licensing

Identify and Validate Innovative Peptides for the Treatment of Obesity

The Pharma Data

MARCH 2, 2021

This new collaboration builds on the positive experience from previous partnerships with Gubra and combines Gubra’s proprietary streaMLine platform and expertise in obesity and peptide chemistry with Boehringer Ingelheim’s expertise in lead optimization and clinical development. population will have obesity. About Boehringer Ingelheim.

In-Vivo

In-Vivo Contract Manufacturing Bioinformatics Clinical Development

Clinical Research Informer

Astellas teams up with UK biotech Mogrify on hearing loss project

Identify and Validate Innovative Peptides for the Treatment of Obesity

Webinars

Stay Connected